Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2009-08-31

AUTHORS

M Lübbert, H Bertz, R Wäsch, R Marks, B Rüter, R Claus, J Finke

ABSTRACT

We have piloted a low-dose schedule of 5-azacytidine followed by donor lymphocyte infusions (DLIs) in patients with relapse of AML or chronic myelomonocytic leukemia (CMMoL) after allografting. Of the 26 patients (median age 62 years, range 28–75) with relapsed AML (n=24) or CMMoL (n=2), 11 (42%) had poor-risk cytogenetics. Twenty-three patients had received fludarabine-based reduced-toxicity conditioning regimens, and three had received conventional myeloablative conditioning. Patients received 5-azacytidine s.c., at a total daily dose of 100 mg, on days 1–3, to be followed by DLI on day 10, with the next course of treatment to be started on day 22. A total of 60 courses of 5-azacytidine were administered, with a median of 2 courses (range: 1–10). In 44 courses, 5-azacytidine was followed by DLI, and thus 19/26 (73%) patients received at least one course of this combined treatment. Clinically relevant neutropenic infections not associated with progressive disease developed in four patients, one of them succumbing to sepsis. Only two patients developed de novo acute GvHD after the combination of 5-azacytidine and DLI. Overall, 66% of the patients benefited from this treatment, with continued CRs achieved in 4 (16%) patients, lasting a median of 525 days (range: 450+ to 820+), and a 50% rate of temporary disease control with stable mixed chimerism (median duration 72 days). The median survival from the start of 5-azacytidine treatment was 136 days (range: 23 to 873+), with an estimated 2-year survival probability of 16%. In conclusion, this non-intensive outpatient regimen of 5-azacytidine followed by DLI is feasible, with a very low aGVHD rate. Objective responses, including continuous complete donor chimerism, occurred also in patients with poor-risk cytogenetics. More... »

PAGES

627-632

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/bmt.2009.222

DOI

http://dx.doi.org/10.1038/bmt.2009.222

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1042146563

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/19718057


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antimetabolites, Antineoplastic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Azacitidine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "DNA Methylation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Epigenesis, Genetic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Graft vs Host Disease", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kaplan-Meier Estimate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukemia, Myeloid, Acute", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukemia, Myelomonocytic, Chronic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphocyte Transfusion", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Recurrence, Local", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pilot Projects", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Stem Cell Transplantation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Transplantation Chimera", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Transplantation Conditioning", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Transplantation, Homologous", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.7708.8", 
          "name": [
            "Division Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "L\u00fcbbert", 
        "givenName": "M", 
        "id": "sg:person.01153663723.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01153663723.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.7708.8", 
          "name": [
            "Division Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bertz", 
        "givenName": "H", 
        "id": "sg:person.01356464223.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356464223.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.7708.8", 
          "name": [
            "Division Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "W\u00e4sch", 
        "givenName": "R", 
        "id": "sg:person.01151333006.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151333006.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.7708.8", 
          "name": [
            "Division Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Marks", 
        "givenName": "R", 
        "id": "sg:person.01201522565.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01201522565.95"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "2Current address: Merck Darmstadt, Darmstadt, Germany", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Division Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany", 
            "2Current address: Merck Darmstadt, Darmstadt, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "R\u00fcter", 
        "givenName": "B", 
        "id": "sg:person.0750355777.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750355777.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "3Current address: Department of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), Heidelberg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.7497.d", 
          "name": [
            "Division Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany", 
            "3Current address: Department of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), Heidelberg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Claus", 
        "givenName": "R", 
        "id": "sg:person.0727645451.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0727645451.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany", 
          "id": "http://www.grid.ac/institutes/grid.7708.8", 
          "name": [
            "Division Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Finke", 
        "givenName": "J", 
        "id": "sg:person.01341317720.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01341317720.21"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.leu.2403412", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012845858", 
          "https://doi.org/10.1038/sj.leu.2403412"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2008.397", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041986402", 
          "https://doi.org/10.1038/leu.2008.397"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bmt.2009.64", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045435788", 
          "https://doi.org/10.1038/bmt.2009.64"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bmt.1704645", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026328513", 
          "https://doi.org/10.1038/sj.bmt.1704645"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bmt.2008.256", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038184380", 
          "https://doi.org/10.1038/bmt.2008.256"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bmt.1705989", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002468461", 
          "https://doi.org/10.1038/sj.bmt.1705989"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1206814", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025860592", 
          "https://doi.org/10.1038/sj.onc.1206814"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bmt.1703028", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035593358", 
          "https://doi.org/10.1038/sj.bmt.1703028"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2009-08-31", 
    "datePublishedReg": "2009-08-31", 
    "description": "We have piloted a low-dose schedule of 5-azacytidine followed by donor lymphocyte infusions (DLIs) in patients with relapse of AML or chronic myelomonocytic leukemia (CMMoL) after allografting. Of the 26 patients (median age 62 years, range 28\u201375) with relapsed AML (n=24) or CMMoL (n=2), 11 (42%) had poor-risk cytogenetics. Twenty-three patients had received fludarabine-based reduced-toxicity conditioning regimens, and three had received conventional myeloablative conditioning. Patients received 5-azacytidine s.c., at a total daily dose of 100\u2009mg, on days 1\u20133, to be followed by DLI on day 10, with the next course of treatment to be started on day 22. A total of 60 courses of 5-azacytidine were administered, with a median of 2 courses (range: 1\u201310). In 44 courses, 5-azacytidine was followed by DLI, and thus 19/26 (73%) patients received at least one course of this combined treatment. Clinically relevant neutropenic infections not associated with progressive disease developed in four patients, one of them succumbing to sepsis. Only two patients developed de novo acute GvHD after the combination of 5-azacytidine and DLI. Overall, 66% of the patients benefited from this treatment, with continued CRs achieved in 4 (16%) patients, lasting a median of 525 days (range: 450+ to 820+), and a 50% rate of temporary disease control with stable mixed chimerism (median duration 72 days). The median survival from the start of 5-azacytidine treatment was 136 days (range: 23 to 873+), with an estimated 2-year survival probability of 16%. In conclusion, this non-intensive outpatient regimen of 5-azacytidine followed by DLI is feasible, with a very low aGVHD rate. Objective responses, including continuous complete donor chimerism, occurred also in patients with poor-risk cytogenetics.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/bmt.2009.222", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1096890", 
        "issn": [
          "0268-3369", 
          "1476-5365"
        ], 
        "name": "Bone Marrow Transplantation", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "45"
      }
    ], 
    "keywords": [
      "donor lymphocyte infusion", 
      "poor-risk cytogenetics", 
      "chronic myelomonocytic leukemia", 
      "lymphocyte infusion", 
      "myelomonocytic leukemia", 
      "de novo acute GVHD", 
      "low-dose schedule", 
      "relapse of AML", 
      "conventional myeloablative conditioning", 
      "temporary disease control", 
      "total daily dose", 
      "stable mixed chimerism", 
      "complete donor chimerism", 
      "low-dose treatment", 
      "acute myeloid leukemia", 
      "neutropenic infection", 
      "acute GVHD", 
      "outpatient regimen", 
      "myeloablative conditioning", 
      "conditioning regimens", 
      "progressive disease", 
      "median survival", 
      "objective response", 
      "older patients", 
      "daily dose", 
      "donor chimerism", 
      "mixed chimerism", 
      "myeloid leukemia", 
      "patients", 
      "day 1", 
      "day 22", 
      "day 10", 
      "disease control", 
      "leukemia", 
      "treatment", 
      "infusion", 
      "AML", 
      "chimerism", 
      "median", 
      "next course", 
      "days", 
      "course", 
      "survival probability", 
      "cytogenetics", 
      "GVHD", 
      "regimens", 
      "regimen", 
      "relapse", 
      "CMMoL", 
      "infection", 
      "disease", 
      "dose", 
      "efficacy", 
      "survival", 
      "total", 
      "rate", 
      "conclusion", 
      "response", 
      "schedule", 
      "control", 
      "start", 
      "conditioning", 
      "combination", 
      "s.", 
      "probability", 
      "Cr"
    ], 
    "name": "Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting", 
    "pagination": "627-632", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1042146563"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/bmt.2009.222"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "19718057"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/bmt.2009.222", 
      "https://app.dimensions.ai/details/publication/pub.1042146563"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:27", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_497.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/bmt.2009.222"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/bmt.2009.222'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/bmt.2009.222'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/bmt.2009.222'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/bmt.2009.222'


 

This table displays all metadata directly associated to this object as RDF triples.

297 TRIPLES      21 PREDICATES      121 URIs      105 LITERALS      29 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/bmt.2009.222 schema:about N0a06a3e2dbc142c1a8d47ca3e1fcbba9
2 N1bc0a1274fb84a94bb3a0ca1d9eed832
3 N211c06107d344bbd83f4055302e84497
4 N2572921c290747acb70de6ad88b533bd
5 N30df0de1d2f34939a41e56a69077790c
6 N3f0d50abbc7848489bd0726221589f6e
7 N47ef68ba2ada4de4bee3101bb188f1e2
8 N5be9e74627084a9c86f2377cbfbeb41b
9 N5f5f53a56f0842f08366c0156dd6771b
10 N63e2bcd3caad4e2084efc335f2f2e222
11 N65269919055c4da0935a491bf5803404
12 N6a670e126527420bb836c3e249610e09
13 N8399095b3f564893844226a0d7fd82a2
14 N8cd05f21a3194a15a5efe9ae196c4646
15 Na2579f7d1812450685a2ba1d80adf8ab
16 Na329a05c30a243c0b934d3be05a3cfb0
17 Nb386a64615a7407ebedc53953c0bb357
18 Nbf4555db0f5c418dbc15e60abdb412bd
19 Nc66436d88ca446e8a742d50e1a9a5a6e
20 Nc6b5cdd219bf4497a1be7d79784bf6fb
21 Nf4525c5a08714a4eb40fc7faac51fe46
22 Nfe597046e99c4c998487e74b2c979530
23 anzsrc-for:11
24 anzsrc-for:1103
25 schema:author Naada727dce964bd1983d7f1bbda13c82
26 schema:citation sg:pub.10.1038/bmt.2008.256
27 sg:pub.10.1038/bmt.2009.64
28 sg:pub.10.1038/leu.2008.397
29 sg:pub.10.1038/sj.bmt.1703028
30 sg:pub.10.1038/sj.bmt.1704645
31 sg:pub.10.1038/sj.bmt.1705989
32 sg:pub.10.1038/sj.leu.2403412
33 sg:pub.10.1038/sj.onc.1206814
34 schema:datePublished 2009-08-31
35 schema:datePublishedReg 2009-08-31
36 schema:description We have piloted a low-dose schedule of 5-azacytidine followed by donor lymphocyte infusions (DLIs) in patients with relapse of AML or chronic myelomonocytic leukemia (CMMoL) after allografting. Of the 26 patients (median age 62 years, range 28–75) with relapsed AML (n=24) or CMMoL (n=2), 11 (42%) had poor-risk cytogenetics. Twenty-three patients had received fludarabine-based reduced-toxicity conditioning regimens, and three had received conventional myeloablative conditioning. Patients received 5-azacytidine s.c., at a total daily dose of 100 mg, on days 1–3, to be followed by DLI on day 10, with the next course of treatment to be started on day 22. A total of 60 courses of 5-azacytidine were administered, with a median of 2 courses (range: 1–10). In 44 courses, 5-azacytidine was followed by DLI, and thus 19/26 (73%) patients received at least one course of this combined treatment. Clinically relevant neutropenic infections not associated with progressive disease developed in four patients, one of them succumbing to sepsis. Only two patients developed de novo acute GvHD after the combination of 5-azacytidine and DLI. Overall, 66% of the patients benefited from this treatment, with continued CRs achieved in 4 (16%) patients, lasting a median of 525 days (range: 450+ to 820+), and a 50% rate of temporary disease control with stable mixed chimerism (median duration 72 days). The median survival from the start of 5-azacytidine treatment was 136 days (range: 23 to 873+), with an estimated 2-year survival probability of 16%. In conclusion, this non-intensive outpatient regimen of 5-azacytidine followed by DLI is feasible, with a very low aGVHD rate. Objective responses, including continuous complete donor chimerism, occurred also in patients with poor-risk cytogenetics.
37 schema:genre article
38 schema:isAccessibleForFree false
39 schema:isPartOf N0344baf2f2df408d9817b8b3aafe5fd1
40 N944c1f9bfd1c41239d56482ac0c8f194
41 sg:journal.1096890
42 schema:keywords AML
43 CMMoL
44 Cr
45 GVHD
46 acute GVHD
47 acute myeloid leukemia
48 chimerism
49 chronic myelomonocytic leukemia
50 combination
51 complete donor chimerism
52 conclusion
53 conditioning
54 conditioning regimens
55 control
56 conventional myeloablative conditioning
57 course
58 cytogenetics
59 daily dose
60 day 1
61 day 10
62 day 22
63 days
64 de novo acute GVHD
65 disease
66 disease control
67 donor chimerism
68 donor lymphocyte infusion
69 dose
70 efficacy
71 infection
72 infusion
73 leukemia
74 low-dose schedule
75 low-dose treatment
76 lymphocyte infusion
77 median
78 median survival
79 mixed chimerism
80 myeloablative conditioning
81 myeloid leukemia
82 myelomonocytic leukemia
83 neutropenic infection
84 next course
85 objective response
86 older patients
87 outpatient regimen
88 patients
89 poor-risk cytogenetics
90 probability
91 progressive disease
92 rate
93 regimen
94 regimens
95 relapse
96 relapse of AML
97 response
98 s.
99 schedule
100 stable mixed chimerism
101 start
102 survival
103 survival probability
104 temporary disease control
105 total
106 total daily dose
107 treatment
108 schema:name Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting
109 schema:pagination 627-632
110 schema:productId N6bb59a3402864e6bb941f475000a4852
111 N7f645240bad34092b41a10363024371a
112 Ne69fdd8ddff34c51852ef22071d64295
113 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042146563
114 https://doi.org/10.1038/bmt.2009.222
115 schema:sdDatePublished 2022-12-01T06:27
116 schema:sdLicense https://scigraph.springernature.com/explorer/license/
117 schema:sdPublisher N5032c973a93f408284e52874386deea4
118 schema:url https://doi.org/10.1038/bmt.2009.222
119 sgo:license sg:explorer/license/
120 sgo:sdDataset articles
121 rdf:type schema:ScholarlyArticle
122 N0344baf2f2df408d9817b8b3aafe5fd1 schema:volumeNumber 45
123 rdf:type schema:PublicationVolume
124 N0a06a3e2dbc142c1a8d47ca3e1fcbba9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Graft vs Host Disease
126 rdf:type schema:DefinedTerm
127 N1bc0a1274fb84a94bb3a0ca1d9eed832 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Kaplan-Meier Estimate
129 rdf:type schema:DefinedTerm
130 N211c06107d344bbd83f4055302e84497 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Azacitidine
132 rdf:type schema:DefinedTerm
133 N2572921c290747acb70de6ad88b533bd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Adult
135 rdf:type schema:DefinedTerm
136 N30df0de1d2f34939a41e56a69077790c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Female
138 rdf:type schema:DefinedTerm
139 N3f0d50abbc7848489bd0726221589f6e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Leukemia, Myeloid, Acute
141 rdf:type schema:DefinedTerm
142 N47ef68ba2ada4de4bee3101bb188f1e2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Male
144 rdf:type schema:DefinedTerm
145 N5032c973a93f408284e52874386deea4 schema:name Springer Nature - SN SciGraph project
146 rdf:type schema:Organization
147 N5be9e74627084a9c86f2377cbfbeb41b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Middle Aged
149 rdf:type schema:DefinedTerm
150 N5f5f53a56f0842f08366c0156dd6771b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Humans
152 rdf:type schema:DefinedTerm
153 N605586fc8b4e4fa687af56d0613b5110 rdf:first sg:person.01201522565.95
154 rdf:rest N78a6f5625a324e4e8a0b61d8891dc88e
155 N63e2bcd3caad4e2084efc335f2f2e222 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Lymphocyte Transfusion
157 rdf:type schema:DefinedTerm
158 N65269919055c4da0935a491bf5803404 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Pilot Projects
160 rdf:type schema:DefinedTerm
161 N692785d60d1e49b4a67ca43623461b51 rdf:first sg:person.01151333006.25
162 rdf:rest N605586fc8b4e4fa687af56d0613b5110
163 N6a670e126527420bb836c3e249610e09 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Drug Administration Schedule
165 rdf:type schema:DefinedTerm
166 N6bb59a3402864e6bb941f475000a4852 schema:name pubmed_id
167 schema:value 19718057
168 rdf:type schema:PropertyValue
169 N78a6f5625a324e4e8a0b61d8891dc88e rdf:first sg:person.0750355777.66
170 rdf:rest Na031e664c87f4b75bdd93d2af346c2a3
171 N7f645240bad34092b41a10363024371a schema:name dimensions_id
172 schema:value pub.1042146563
173 rdf:type schema:PropertyValue
174 N834c81aa3bc447e9925df42ffed208a3 rdf:first sg:person.01356464223.06
175 rdf:rest N692785d60d1e49b4a67ca43623461b51
176 N8399095b3f564893844226a0d7fd82a2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Antimetabolites, Antineoplastic
178 rdf:type schema:DefinedTerm
179 N8cd05f21a3194a15a5efe9ae196c4646 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name DNA Methylation
181 rdf:type schema:DefinedTerm
182 N944c1f9bfd1c41239d56482ac0c8f194 schema:issueNumber 4
183 rdf:type schema:PublicationIssue
184 Na031e664c87f4b75bdd93d2af346c2a3 rdf:first sg:person.0727645451.47
185 rdf:rest Nb13144f8c82f4a44ba6f0931055a2ccf
186 Na2579f7d1812450685a2ba1d80adf8ab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Transplantation, Homologous
188 rdf:type schema:DefinedTerm
189 Na329a05c30a243c0b934d3be05a3cfb0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Transplantation Chimera
191 rdf:type schema:DefinedTerm
192 Naada727dce964bd1983d7f1bbda13c82 rdf:first sg:person.01153663723.53
193 rdf:rest N834c81aa3bc447e9925df42ffed208a3
194 Nb13144f8c82f4a44ba6f0931055a2ccf rdf:first sg:person.01341317720.21
195 rdf:rest rdf:nil
196 Nb386a64615a7407ebedc53953c0bb357 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
197 schema:name Stem Cell Transplantation
198 rdf:type schema:DefinedTerm
199 Nbf4555db0f5c418dbc15e60abdb412bd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
200 schema:name Leukemia, Myelomonocytic, Chronic
201 rdf:type schema:DefinedTerm
202 Nc66436d88ca446e8a742d50e1a9a5a6e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
203 schema:name Epigenesis, Genetic
204 rdf:type schema:DefinedTerm
205 Nc6b5cdd219bf4497a1be7d79784bf6fb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
206 schema:name Aged
207 rdf:type schema:DefinedTerm
208 Ne69fdd8ddff34c51852ef22071d64295 schema:name doi
209 schema:value 10.1038/bmt.2009.222
210 rdf:type schema:PropertyValue
211 Nf4525c5a08714a4eb40fc7faac51fe46 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
212 schema:name Neoplasm Recurrence, Local
213 rdf:type schema:DefinedTerm
214 Nfe597046e99c4c998487e74b2c979530 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
215 schema:name Transplantation Conditioning
216 rdf:type schema:DefinedTerm
217 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
218 schema:name Medical and Health Sciences
219 rdf:type schema:DefinedTerm
220 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
221 schema:name Clinical Sciences
222 rdf:type schema:DefinedTerm
223 sg:journal.1096890 schema:issn 0268-3369
224 1476-5365
225 schema:name Bone Marrow Transplantation
226 schema:publisher Springer Nature
227 rdf:type schema:Periodical
228 sg:person.01151333006.25 schema:affiliation grid-institutes:grid.7708.8
229 schema:familyName Wäsch
230 schema:givenName R
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151333006.25
232 rdf:type schema:Person
233 sg:person.01153663723.53 schema:affiliation grid-institutes:grid.7708.8
234 schema:familyName Lübbert
235 schema:givenName M
236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01153663723.53
237 rdf:type schema:Person
238 sg:person.01201522565.95 schema:affiliation grid-institutes:grid.7708.8
239 schema:familyName Marks
240 schema:givenName R
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01201522565.95
242 rdf:type schema:Person
243 sg:person.01341317720.21 schema:affiliation grid-institutes:grid.7708.8
244 schema:familyName Finke
245 schema:givenName J
246 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01341317720.21
247 rdf:type schema:Person
248 sg:person.01356464223.06 schema:affiliation grid-institutes:grid.7708.8
249 schema:familyName Bertz
250 schema:givenName H
251 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356464223.06
252 rdf:type schema:Person
253 sg:person.0727645451.47 schema:affiliation grid-institutes:grid.7497.d
254 schema:familyName Claus
255 schema:givenName R
256 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0727645451.47
257 rdf:type schema:Person
258 sg:person.0750355777.66 schema:affiliation grid-institutes:None
259 schema:familyName Rüter
260 schema:givenName B
261 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750355777.66
262 rdf:type schema:Person
263 sg:pub.10.1038/bmt.2008.256 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038184380
264 https://doi.org/10.1038/bmt.2008.256
265 rdf:type schema:CreativeWork
266 sg:pub.10.1038/bmt.2009.64 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045435788
267 https://doi.org/10.1038/bmt.2009.64
268 rdf:type schema:CreativeWork
269 sg:pub.10.1038/leu.2008.397 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041986402
270 https://doi.org/10.1038/leu.2008.397
271 rdf:type schema:CreativeWork
272 sg:pub.10.1038/sj.bmt.1703028 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035593358
273 https://doi.org/10.1038/sj.bmt.1703028
274 rdf:type schema:CreativeWork
275 sg:pub.10.1038/sj.bmt.1704645 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026328513
276 https://doi.org/10.1038/sj.bmt.1704645
277 rdf:type schema:CreativeWork
278 sg:pub.10.1038/sj.bmt.1705989 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002468461
279 https://doi.org/10.1038/sj.bmt.1705989
280 rdf:type schema:CreativeWork
281 sg:pub.10.1038/sj.leu.2403412 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012845858
282 https://doi.org/10.1038/sj.leu.2403412
283 rdf:type schema:CreativeWork
284 sg:pub.10.1038/sj.onc.1206814 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025860592
285 https://doi.org/10.1038/sj.onc.1206814
286 rdf:type schema:CreativeWork
287 grid-institutes:None schema:alternateName 2Current address: Merck Darmstadt, Darmstadt, Germany
288 schema:name 2Current address: Merck Darmstadt, Darmstadt, Germany
289 Division Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany
290 rdf:type schema:Organization
291 grid-institutes:grid.7497.d schema:alternateName 3Current address: Department of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), Heidelberg, Germany
292 schema:name 3Current address: Department of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), Heidelberg, Germany
293 Division Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany
294 rdf:type schema:Organization
295 grid-institutes:grid.7708.8 schema:alternateName Division Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany
296 schema:name Division Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany
297 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...